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Objectives To estimate the absolute numbers of breast cancer deaths prevented and the absolute
numbers of tumours overdiagnosed in mammographic screening for breast cancer at ages 50–69
years.
Setting The Swedish Two-County randomized trial of mammographic screening for breast cancer,
and the UK Breast Screening Programme in England, ages 50–69 years.
Methods We estimated the absolute numbers of deaths avoided and additional cases diagnosed in
the study group (active study population) of the Swedish Two-County Trial, by comparison with the
control group (passive study population). We estimated the same quantities for the mortality and
incidence rates in England (1974–2004 and 1974–2003, respectively). We used Poisson
regression for statistical inference.
Results A substantial and signiﬁcant reduction in breast cancer mortality was associated with
screening in both the Two-County Trial (P , 0.001) and the screening programme in England (P ,
0.001). The absolute beneﬁts were estimated as 8.8 and 5.7 breast cancer deaths prevented per
1000 women screened for 20 years starting at age 50 from the Two-County Trial and screening
programme in England, respectively. The corresponding estimated numbers of cases overdiagnosed
per 1000 women screened for 20 years were, respectively, 4.3 and 2.3 per 1000.
Conclusions The beneﬁt of mammographic screening in terms of lives saved is greater in absolute




stimation of the absolute beneﬁts and harms of
mammographic screening for breast cancer remains
a subject of discussion. The estimates from individual
randomized trials and service screening programmes suggest
that between 300 and 500 women need to be screened every
2–3 years for 10 years to prevent one death from breast
cancer.
1,2 Harms of screening include the anxiety and incon-
venience associated with screening and with suspicious
screening ﬁndings, which do not result in a diagnosis of
cancer, and overdiagnosis, the last of which has attracted
considerable interest recently.
3–6
Overdiagnosis is deﬁned as the diagnosis of a cancer as a
result of screening that would not have been diagnosed in
the woman’s lifetime had screening not taken place.
Estimates of overdiagnosis range from less than 10% of
tumours diagnosed in a screening programme to around
50%.
3,4,7,8
There is a majority of view that the beneﬁts of breast
screening outweigh the harms,
9,10 although debate on
target age ranges remains.
11 Recently, however, it has
been claimed that the beneﬁts in terms of lives saved are
much smaller, and the harm in terms of overdiagnosis
much larger, than had previously been thought. Gøtzsche
et al.
6 have asserted that for 2000 women screened for 10
years, only one life will be saved and six additional cases
will be diagnosed. The accuracy of these claims has been
questioned, however.
12 It is therefore worthwhile to seek
estimates from randomized trials and service screening to
conﬁrm or refute these claims.
The Swedish Two-County Trial was the ﬁrst published
randomized trial of breast screening using mammography
as the sole screening modality.
13 Its primary result was a
30% reduction in breast cancer mortality with the offer of
screening. Its design and results informed decision-making
in setting up the UK National Breast Screening
Programme.
14
In this paper, we analyse breast cancer incidence and mor-
tality data from both the Swedish Two-County Trial and the
general female population in England before and after the
inception of the screening programme. We derive simple
deterministic estimates from both sources of the number of
25
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breast cancer screening.
MATERIALS ANDMETHODS
The Swedish Two-County Trial has been described pre-
viously. Brieﬂy, 55,985 women aged 40–74 were allocated
to invitation to periodic mammographic screening (active
study population, ASP) and 77,080 to no invitation
(passive study population, PSP). Women in the ASP aged
40–49 at allocation were offered screening on average
every 24 months. Women aged 50–74 were offered screen-
ing every 33 months. After 6–7 years, the PSP was invited to
screening and the screening phase of the trial closed,
15 but
follow-up continued for deaths from breast cancers diag-
nosed during the screening phase. Subjects were random-
ized between 1977 and 1981 and spent an average of
seven years in the screening phase of the trial. Thus, the
screening in the trial took place between 1977 and 1988.
In this paper, we have data on deaths till the end of 1998,
a maximum of 21.5 years follow-up.
The UK National Breast Screening Programme was
launched in 1988, although only approximately 2.5% of
the target population was screened in that year. We there-
fore consider the screening epoch to be 1989 and thereafter.
The programme was built up during the period 1989–1993.
It offers three-yearly mammography screening. Originally,
the age range intended was 50–64 years. In 2002–2004,
this was expanded to 50–70 years, and a further expansion
to the range 47–73 years is in progress. We have data by
ﬁve-year age group and calendar year on breast cancer inci-
dence between 1974 and 2003 and breast cancer mortality
between 1974 and 2004, with the corresponding population
denominators.
For the estimation of the absolute beneﬁt of screening
from the Two-County Trial, we used the same methodology
as described previously,
1 but applied it speciﬁcally to the age
group 50–69 at randomization, to correspond approximately
to the target group of the UK programme. Essentially we
established the deﬁcit in deaths from breast cancer in the
study group compared with the control group and the
numbers in the study group who were screened. Dividing
the latter by the former gives an estimate of the number of
women needed to screen to save one life. For the estimation
of the beneﬁt from the English Breast Cancer mortality data,
we used Poisson regression to compare the difference in
breast cancer mortality for ages 50–69 years between 1995
onwards and pre-1989 with that observed for other age
groups. We calculated the absolute number of deaths
prevented as the difference between those observed and
those expected on the basis of the mortality changes in
age groups ,50 and 70 years or more. This is conservative
because some of the deaths observed from 1995 onwards
will be from tumours diagnosed before 1989, when there
was no screening, and because some deaths in the period
1989–1994 will have been prevented by screening.
2
The estimation of overdiagnosis is more complicated. In
the Swedish Two-County Trial, we ﬁrst estimated the
expected incidence in the absence of screening as follows:
from the incidence in the control group, we used Poisson
regression to estimate the trend in incidence in the ﬁrst six
years of the trial, before any screening of the control group
in this age group took place in order that our estimate of
the underlying incidence trend was not contaminated by
screening. From the trend we estimated the expected
average incidence in year 4 after randomization, the mid-
point of the screening phase of the trial.
Subjects in the ASP were invited to one prevalence screen
and, on average, two incidence screens. Let P be the observed
prevalence at ﬁrst screen in the ASP, Q the observed preva-
lence at the ﬁrst screen of the PSP at closure of the screening
phase, PT the unknown prevalence of true cases at ﬁrst screen
in the ASP, PO the unknown prevalence of overdiagnosed
c a s e sa tﬁ r s ts c r e e ni nt h eA S P ,ST the rate of true cases at inci-
dence screen, SO the unknown rate of overdiagnosed cases at
incidence screen, I the average annual incidence in the ASP
during the screening phase, Ie the expected average annual
incidence from PSP, t the relative incidence of breast cancer
after seven years (i.e. at the end of the trial), taking into
account age and time trends. As entry to the trial was in the
period 1977–1981, this seven-year period pertains mostly to
the early 1980s, where a1 is the proportion attending ﬁrst
screen of ASP and a2 is the proportion attending incidence
screens of ASP.
The following equations will therefore hold:
A1PO þ 2a2SO ¼ 7Ie  ð 7 þ 1:2ÞIe ð1Þ
PO þ PT ¼ P ð2Þ
PO þ tPT ¼ Q ð3Þ
Here we are assuming that the same rate of overdiagnosed
cases applies to the ﬁrst screen of the ASP and PSP (approxi-
mately seven years older at the time of ﬁrst screen), but that
the true cases will reﬂect the trend with age and time. After
excluding the prevalence screen, at which most length bias
or overdiagnosis is likely to take place,
5,7,8 the age at diagno-
sis in the ASP was 1.2 years on average younger than that in
the PSP, suggesting a 1.2 year correction for overdiagnosis in
equation (1). The exclusion of all of the prevalence screen
cases in the estimation of lead time is likely to be conserva-
tive. P, Q, I, a1 and a2 were all directly observed from the trial
data. Ie was observed in the PSP before the prevalence screen
of this group and t was estimated from changes in breast
cancer incidence by age and time from Swedish national
statistics.
16,17 In equation (1) we approximated the average
expected incidence by the ﬁtted incidence in year 4, the
midpoint of the seven-year screening phase. Equations
(1)–(3) were then solved for the three unknown quantities
PO, PT and SO.
For the estimation of overdiagnosis from the English inci-
dence data, we analysed age groups ,45, 45–49, 50–64,
65–69 and 70þ separately. We ﬁrst estimated the log–linear
trends in incidence from 1974 to 1988, before the screening
programme started, using Poisson regression. We then pro-
jected these to estimate the expected incidence in 1989–
2003. To adjust for any non-linear trends in log incidence,
we re-estimated the expected incidence relative to age group
,45, in which very little screening took place (some women
receive their ﬁrst invitation before age 50 but very few before
age 45). This entailed dividing the expected numbers by the
relative excess for the under 45 age group.
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age groups 45–49 and 50–64, minus any deﬁcit in age
groups 65–69 and 70þ, which is the sum of the observed
minus expected ﬁgures for the four age groups.
RESULTS
Absolutenumbers of livessaved
In the ASP of the Swedish Two-County Trial at ages 50–69
years, 90% attended the prevalence screen and 83% on
average the two incidence screens.
15 Table 1 shows breast
cancer deaths, population sizes and numbers screened,
with relative risk (RR), absolute number of breast cancer
deaths prevented and the estimated number needed to
screen to save one life. The RR of breast cancer death in
the ASP compared with the PSP was 0.62 (95% CI 0.51–
0.75). There were 201 breast cancer deaths in the ASP com-
pared with 325 expected from the PSP (46,897   229/
33,074). Thus, the estimated number of deaths prevented
was 124, and the number needed to screen was 323
(40,060/124). This was the result of screening every 2–3
years for a period of seven years. With screening for 20
years at the same interval, one would anticipate 354 breast
cancer deaths prevented (8.8 per thousand screened), and
a number needed to screen of 113 to prevent one breast
cancer death.
Figure 1 shows breast cancer mortality in England by time
for age groups ,50, 50–69 and 70þ. There was a sharp
decrease in mortality from the mid-1990s in the age group
50–69. In women aged ,50, there was a lesser reduction
in mortality, although this is difﬁcult to see in the ﬁgure
due to the rarity of breast cancer at younger ages. In the
70þ age group, there was a rise in mortality in the early
1990s then a fall back to 1980s’ levels. Table 2 shows the
mortality rates and RRs for the three age groups, and
periods 1974–1988, 1989–1994 and 1995 onwards. The
table also shows observed and expected numbers of deaths
in 1995 onwards. Compared with other age groups there
was a highly signiﬁcant 28% reduction in breast cancer mor-
tality in the age group invited to screening (RR 0.72, 95% CI
0.70–0.74, P , 0.001). The deﬁcit in breast cancer deaths
was 53,057–38,201 ¼ 14,856. This corresponds to approxi-
mately 52 million person-years of screening, which implies
5.7 breast cancer deaths prevented for 1000 women




15 From Swedish national incidence rates pub-
lished in Cancer Incidence in Five Continents,
16,17 it was estimated
as 1.35. Since I is the average incidence during the screening
phase, we calculate it as the number of cases divided by seven
times the average population during the screening phase.
There were 46,897 women in the ASP in this age group, an
average population during the screening phase of 45,155 and
911 cases diagnosed during the screening phase. This gave I
¼ 911/(7   45,155) ¼ 0.0029. Attendance at ﬁrst screen of
the ASP (a1) was 90% and the corresponding prevalence (P)
was 0.0068. Average attendance at the two incidence screens
in the ASP (a2) was 83%. Attendance at the ﬁrst screen of
the PSP at closure of the screening phase was 84% and preva-
lence (Q) was 0.0085. Equations (2) and (3) are therefore
PO þ PT ¼ 0:0068
and
PO þ 1:35PT ¼ 0:0085:
This gives PT ¼ 0.0049 and PO ¼ 0.0019. Substituting PO in
equation (1) gives
0:9   0:0019 þ 2   0:83   SO ¼ 7   0:0028   8:2   0:0021:
This in turn gives SO ¼ 0.0004, and a total overdiagnosis
of 2.4 per 100c in the ASP, approximately 12% of cancers
diagnosed. For per 1000 women screened seven times over
20 years, the expected number of overdiagnosed cases
would be 1.9 þ 6   0.4 ¼ 4.3. With the estimated lives
saved for this number of 8.8 per 1000, this means that for
every two breast cancer deaths prevented, one might
expect one overdiagnosed case. Put another way, for every
11 cases diagnosed, two lives will be saved, and one case
will be overdiagnosed.
Figure 2 shows breast cancer incidence in England by age
and time. Clearly, incidence was increasing prior to screen-
ing in all age groups and continued to do so thereafter,
with a particular strong increase in age group 50–64 in
the early years of the programme. A corresponding deﬁcit
can be seen shortly afterwards in the 65–69 age group,
which also showed a sharp increase in 2002–2003 when
the programme was expanded to include ages up to 70
Table 1 Calculation of the number needed to screen to
prevent one breast cancer death in the Swedish Two-County
Trial, ages 50–69 years at randomization
Quantity ASP PSP
Number of subjects 46,897 33,074
Average number screened 40,060 –
Breast cancer deaths 201 229
Rate/1000 4.3 6.9
Deaths expected in ASP 325 –
Deaths avoided in ASP 124 –
Number needed to screen  323 –
ASP, active study population; PSP, passive study population
 Number needed to screen to prevent one breast cancer death
Figure 1 Breast cancer mortality in England 1974–2004
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lower than that which would have been observed if prescre-
ening trends had persisted. Table 3 shows the observed and
expected numbers of cases by age group in years 1989–
2003, standardized to the age group ,45. There was an
excess of a total of 25,042 tumours in age groups 45–64,
but a deﬁcit of 18,981 in ages 65 years and over. The net
excess was therefore 6061 breast cancers. Taking this as
the estimate of overdiagnosis from the 52 million person-
years of screening, we estimate 2.3 cases overdiagnosed
per 1000 women screened for 20 years. Thus, for every
two breast cancer deaths prevented in the UK programme,
we estimate that there is less than one overdiagnosed case.
And for approximately every 28 cases diagnosed, 2.5 lives
were saved and one case overdiagnosed. The larger
number of tumours diagnosed per life saved and per over-
diagnosed case is due to the higher incidence and greater
survival in the late 1990s and early 21st century compared
with the late 1970s and early 1980s.
DISCUSSION
Our estimates of the absolute beneﬁts of screening were 8.8
and 5.7 breast cancer deaths prevented per 1000 women
screened for 20 years from age 50, from the Swedish
Two-County Trial and the Breast Screening Programme in
England, respectively. The corresponding estimated over-
diagnosed cases were 4.3 and 2.3 per 1000 over 20 years.
This implies that in a cohort screened every three years for
the 20 years from age 50 between 9% and 13% of cases
diagnosed have their lives saved, and between 4% and 7%
of cases are overdiagnosed. Thus, the beneﬁts in terms of
numbers of deaths prevented are around double the harms
in terms of overdiagnosis. Analysis of both data-sets shows
a substantial and signiﬁcant reduction in breast cancer
deaths in association with mammographic screening. This
beneﬁt is greater in absolute terms than the harm of
overdiagnosis.
Our estimated beneﬁt is somewhat larger than our pre-
vious estimates, which warrants some explanation.
1,2 In
this study we evaluated screening in the age group 50–69,
whereas the previous estimates pertained to the age Figure 2 Breast cancer incidence in England 1974–2003
Table 3 Observed cases of breast cancer in England 1989–2003, with expected cases calculated by extrapolation of pre-1988
trends and standardized to the age group ,45 years
Age group Observed (O) cases Expected (E) cases  O 2 E RR (95% CI)
,45 54,780 54,780 0 1.00 (–)
45–49 42,962 40,467 2,495 1.06 (1.04–1.08)
50–64 168,253 145,706 22,547 1.15 (1.13–1.17)
65–69 47,044 49,844 22,800 0.94 (0.92–0.96)
70þ 168,656 184,837 216,181 0.91 (0.90–0.92)
RR, relative risk
 Standardized to the age group ,45
Table 2 Breast cancer mortality rates in England by age group, 1974–2004, with RRs, 95% CIs and observed/expected
numbers of deaths in 1995–2004
Age group Quantity 1974–1988 1989–1994 1995–2004
Observed (expected)
number of deaths 1995–2004
,50 OR 1.00 0.99 0.82 12,623 (15,394)
95% CI (–) (0.96–1.02) (0.80–0.84)
Rate/100,000 9.4 9.3 7.7
50–69 OR 1.00 0.97 0.73 38,201 (52,330)
95% CI (–) (0.95–0.99) (0.72–0.74)
Rate/100,000 97.7 94.6 71.5
70þ OR 1.00 1.14 1.01 58,536 (57,956)
95% CI (–) (1.12–1.16) (0.99–1.03)
Rate/100,000 170.6 194.3 172.2
50–69 (adjusted
for other ages) 
OR NA 0.84 0.72 38,201 (53,057)
95% CI (0.82–0.86) (0.70–0.74)
RR, relative risk; OR, odds ratio, NA, not applicable
 Adjusted RR for 1995–2004 is calculated as the unadjusted RR compared with 1974–1988 in the 50–69 age group, divided by the corresponding RR calculated for the other age groups
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tality from breast cancer and the effect of screening would
be attenuated in comparison with 50–69. Our estimated
absolute number of lives saved is considerably larger than
that of a number of other studies.
6,18 As has been pointed
out in the past, however, the latter have suffered from con-
fusion of actual screening with invitation to screening, con-
fusion of follow-up periods with screening periods and
exclusion of other relevant information.
12,19,20
Ifweconsiderthatintheunscreenedagegroups,cruderates
of breast cancer incidence increased while mortality remained
stable, it is clear that other factors such as improvements in
treatment and earlier symptomatic diagnosis have also
improved breast cancer’s prognosis in the UK during the
period under study. The reduction in mortality in the age
group 50–69, however, indicates that the policy of screening
has conferred a further 28% mortality reduction.
Our estimates of overdiagnosis are higher than our pre-
vious estimates from multistate modelling.
7 As noted
above, the ﬁgure from the Swedish Two-County Trial may
be an overestimate of overdiagnosis. It is also possible that
the multistate models somewhat underestimate overdiagno-
sis due to strong negative co-linearity with estimated
screening sensitivity. Our present results lie between our
previous estimates and those of the Advisory Committee
on Breast Cancer Screening,
21 which estimated that one in
eight women who are routinely screened and are diagnosed
with breast cancer have a breast cancer diagnosed,
which would not have arisen in the absence of screening,
and one in eight fewer such women would die of breast
cancer.
These results are in stark contrast to those of Gøtzsche
et al.,
6 who have claimed that the overdiagnosed cases are
10 times more common than the breast cancer deaths pre-
vented. The reason for this disagreement partly lies in the
fact that our beneﬁt is estimated directly from empirical
data, and we have been careful to avoid confusing invitation
to screening with actually receiving screening. It may also be
due to the time frames in the two sets of estimates. Gøtzsche
and colleagues base their estimates on cases and deaths
occurring during a 10-year screening period. Much of the
beneﬁt of screening in a 10-year period will actually be
observed after that period, and excess cases occurring
during that period may be compensated for by a future
deﬁcit in incidence. This emphasizes that to estimate absol-
ute beneﬁts and harms, long periods of follow-up are
necessary. Interestingly, Jørgensen and Gøtzsche
22 recently
estimated a 57% excess incidence in the screening age
range in the ﬁrst seven years of the UK programme and
interpreted this as entirely due to overdiagnosis. This in
turn would imply that 36% of the tumours diagnosed in
this age group and period were overdiagnosed. Since only
37% of breast cancers were diagnosed by screening during
this period,
23 this would mean that almost 100% of
screen-detected cancers would never have arisen during
the lifetimes of the patients, which is an absurd and
frankly incredible conclusion. We obtained less extreme
and more credible estimates by having a longer observation
period, incorporating the deﬁcit in incidence after the
upper age limit for screening and taking fuller account of
other changes in incidence occurring independently of
screening.
We have deliberately derived simple age-speciﬁc estimates
from the English incidence and mortality rates. More
complex age–period–cohort analyses might yield different
estimates, although they would also have ambiguities of
interpretation, due to the possibility of over-adjustment of
potential effects of screening on incidence or mortality. At
any rate, our estimates from both service screening and a
major randomized trial show that there is a worthwhile
beneﬁt of mammography in terms of lives saved, and that
this signiﬁcantly exceeds any harm in the form of overdiag-
nosis that may occur.
...............
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